Skip to main content
. Author manuscript; available in PMC: 2021 Dec 16.
Published in final edited form as: Sci Transl Med. 2021 Jul 14;13(602):eabg6128. doi: 10.1126/scitranslmed.abg6128

Fig. 5. Epitope diversity of immune sera characterized by competition assays.

Fig. 5.

(A) The results of a BLI-based competition assay whereby biotinylated GP was immobilized on a streptavidin sensor and saturated with preinfection sera are shown. MAbs were then applied to compete for a specific epitope. The level of inhibition is determined as a percentage of blocking activity compared to negative control sera against the tested mAb. Symbols indicate individual NHPs. Gray bars denote the average blocking of mAbs by sera from vaccinated groups ± SEM. Open symbols indicate nonsurvivors. (B) The percentage of mAb epitope binding inhibition for NHPs organized according to survivors (gray circles) and nonsurvivors (black squares) is shown. Significance measured by two-way ANOVA with (A) Tukey’s correction for multiple comparisons between vaccine groups and Sidak’s correction for multiple comparisons between (A) time points and between (B) survivors and nonsurvivors. *P ≤ 0.05, **P ≤ 0.01, ***P ≤ 0.001, and ****P ≤ 0.0001.